iMetabolic Biopharma is advancing its early stage pipeline based upon the application of the iPlatform™ . Pipeline asset functions currently include, but are not limited to: protein silencing, protein level gene therapy and target protein replacement.
The net result is the production of therapeutic molecules that elicit clinically desired results with improved targeting, more precision and improved safety all at a lower cost.
Due to superior operational efficiency, iMBP has been able to expedite the evolution of its pipeline. With accelerating program development, it is the goal of the company to continue in this pipeline maturation and subsequent expansion.
The continuous addition of new pipeline assets allows for iMBP to develop a business model based on longevity. The scalability of the iPlatform™ provides a sustainable mechanism for company de-risking, growth and valuation